We recently released a list 10 stocks of billionaire Andreas Halvorsen have huge upward potential. In this article, we will explore the stock picks of Newamsterdam Pharma Company NV (NASDAQ:NAMS) with other billionaire Andreas Halvorsen, with huge upside potential.
Ole Andreas Halvorsen is one of the most important names among former employees under Julian Robertson’s Tiger Management. Robertson formed a team of powerful young businessmen (called Tiger Bears) in the 1990s, and most of them built their own hedge funds after exiting. Some other notable names include Robert Citrone, Chase Coleman and John Griffin. Halwatson is the richest tiger cub. Forbes magazine ranked 382nd among the world's richest people on the 2025 list with a net worth of $8 billion.
The Norwegian billionaire founded Viking Global Investor Records in 1999 with former Tiger management employees Brian Olson and David Ott. Halvorsen is an equity trader at Tiger Management, where the strategies and principles he uses form the core foundation of Viking’s global approach. The fund conducts extensive due diligence on various companies to identify undervalued (long) or overvalued (short) stocks. In short, Halvorsen uses the classic long/short stock strategy to generate many returns.
Please read also: 10 Big Stocks of Billionaire Steve Cohen with Huge Up Potential and Billionaire Prem Watsa's 10 Stocks with Highest Potential.
But above all, Halvorsen is popular with his bold bets. In many cases, these bets return huge gains. For example, in the first year of Viking Global's existence, the fund returned 89% after the fee. Recently, in the fourth quarter of 2024, billionaires took three banks to hold the highest stakes. As of April 2025, the banking industry (in Halvorsen's portfolio) performed well and was the only area year by year.
If anything, Halvorsen's method teaches that playing long games can be an excellent strategy for favorable improvement. Many stocks in Viking’s global portfolio have been there for many years and are usually purchased in less popular situations. From then on, it is prudent to check the stocks invested by billionaires, especially those with huge upward potential.
We reviewed the Viking Global First Quarter 2024 second 13F files to compile this list. Of the 86 holdings, we focus only on the company's stocks and exclude the interests of ETFs and options. From the results, we selected the top 10 stocks with the highest upside potential (as of April 28). Additionally, we have mentioned hedge fund sentiment around the fourth stock in Q4 2024.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
Ole Andreas Halvorsen of Viking Global
As of April 28: 145.43% upward potential
Viking Global Bet Value: $179,348,324
Number of hedge fund holders: 36
Newamsterdam Pharma Company NV (NASDAQ:NAMS) is another biopharmaceutical company in Halvorsen's portfolio with high upside potential. The company has developed treatments for cardiovascular diseases. Its main product is obicetrapib.
Newamsterdam Pharma Company NV (NASDAQ:NAMS) reported $45.6 million in 2024 revenue, more than triple the figure in the same quarter of 2023. This growth is primarily driven by milestone realization of clinical success and recognition related to general development cost repayment. The company ended on December 31, 2024 with cash and cash equivalents of $771.7 million and $62.5 million in marketable securities, up from $340.5 million at the end of 2023.
The company's regulatory and commercial advances continue to move forward. Newamsterdam Pharma Company NV (NASDAQ:NAMS) expects its partner Menarini to receive European marketing approval in the second half of 2025. Meanwhile, the company's three-phase phase three prevalent cardiovascular outcome trials are still on the track, with more than 9,500 patients on the track. On April 17, 2025, Jefferies analyst Dennis Ding maintained a buy rating on Newamsterdam Pharma Company NV (NASDAQ:NAMS) and set its target target at $45.00. The company's stock is currently $17.52, close to its 52-week low of $14.06. This shows that there is huge upward potential based on analyst expectations.
Overall, NAM Ranked second There is huge upside potential in the stock picks of our billionaire Andreas Halvorsen. Although we acknowledge the potential of NAM as an investment, our belief is that AI stocks have higher returns in a shorter time frame and offer greater hope in this. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for more promising AI stocks than NAM, but whose earnings are trading at less than 5 times the price, check out our report The cheapest AI stock.
Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.
Disclosure: None. This article was originally published in Internal monkey.